Skip to main content

Table 4 Medical decision making on adjuvant treatment

From: Clinical management of gastric cancer: results of a multicentre survey

Adjuvant practice

Recommendation of the Guidelines

Oncological surgeons

Medical oncologists

Radiation oncologists

p

  

N

%

N

%

N

%

 

moderately differentiated adenocarcinoma pT4N0M0 after gastrectomy

postoperative chemoradiation

      

0.007

observe without postoperative treatment

 

19

18.81

0

0

0

0

 

postoperative chemotherapy

 

57

56.44

102

63.35

26

27.08

 

postoperative radiotherapy

 

0

0

0

0

7

7.29

 

postoperative chemoradiation

 

25

24.75

59

36.65

63

65.63

 

moderately differentiated adenocarcinoma pT4N0M0 after gastrectomy

Systemic chemotherpy

      

< 0.001

Systemic chemotherapy

 

73

72.28

89

55.28

75

78.13

 

Intraperitoneal chemotherapy(IP)

 

0

0

0

0

0

0

 

Systemic chemotherapy+IP

 

28

27.72

72

44.72

21

21.88

 

Other

 

0

0

0

0

0

0

 

moderately differentiated adenocarcinoma invaded muscularis and vascular without metastasis in the 16 removed regional lymph nodes

postoperative chemotherapy

      

0.044

observe without postoperative treatment

 

41

40.59

37

22.98

26

27.08

 

postoperative chemotherapy

 

46

45.54

73

45.34

38

39.58

 

postoperative radiotherapy

 

0

0

0

0

13

13.54

 

postoperative chemoradiation

 

14

13.86

51

31.68

19

19.79

 

other

 

0

0

0

0

0

0

 

poor differentiated adenocarcinoma invaded muscularis without metastasis in the 16 removed regional lymph nodes

postoperative chemotherapy

      

0.053

observe without postoperative treatment

 

52

51.49

21

13.04

17

17.71

 

postoperative chemotherapy

 

43

42.57

140

86.96

58

60.42

 

postoperative radiotherapy

 

3

2.97

0

0

0

0

 

postoperative chemoradiation

 

3

2.97

0

0

21

21.88

 

other

 

0

0

0

0

0

0

 

well differentiated adenocarcinoma invaded muscularis without metastasis in the 6 removed regional lymph nodes

observe without postoperative treatment

      

0.020

observe without postoperative treatment

 

29

28.71

68

42.24

36

37.50

 

postoperative chemotherapy

 

66

65.35

61

37.89

36

37.50

 

postoperative radiotherapy

 

0

0

0

0

5

5.21

 

postoperative chemoradiation

 

6

5.94

32

19.88

19

19.79

 

other

 

0

0

0

0

0

0

 

when begin adjuvant chemotherapy after gastrectomy

NA

      

0.233

1-2 w

 

13

12.87

28

17.39

11

11.46

 

3-4 w

 

82

81.19

133

82.61

79

82.29

 

5-6 w

 

4

3.96

0

0

6

6.25

 

≥ 6 w

 

2

1.98

0

0

0

0

 

regimen usually used in adjuvant setting (without neoadjuvant chemotherapy)

CF(DDP+5FU) or fluoropyrimidine(5Fu or Capecitabine)

      

0.383

CF(DDP+5FU)

 

18

17.82

21

13.04

12

12.50

 

ECF(EPI+DDP+5FU)

 

12

11.88

25

15.53

7

7.29

 

fluoropyrimidine(5Fu or Capecitabine)

 

12

11.88

11

6.83

11

11.46

 

oxaliplatin based regimen

 

34

33.66

69

42.86

44

45.83

 

irinotecan based regimen

 

20

19.80

8

4.97

9

9.38

 

paclitaxel or docetaxel based regimen

 

5

4.95

24

14.91

8

8.33

 

combination of above or other

 

0

0

3

1.86

5

5.21

 

how long adjuvant chemtherapy last

NA

      

0.220

1-3 m

 

11

10.89

2

1.24

11

11.46

 

4-6 m

 

71

70.30

144

89.44

63

65.63

 

7-9 m

 

7

6.93

3

1.86

7

7.29

 

10-12 m

 

5

4.95

5

3.11

8

8.33

 

≥ 12 m

 

3

2.97

4

2.48

7

7.29

 

3-6 m in the first year, then 2-3 m annually for 2-3 y

 

4

3.96

3

1.86

0

0

 

other

 

0

0

0

0

0

0

Â